about
The effect of angiotensin II receptor blockers on hyperuricemiaSafety risks with investigational drugs: Pharmacy practices and perceptions in the veterans affairs health system.Characteristics of Postgraduate Year 1 Pharmacy Residency Programs at Veterans Affairs Medical CentersUse of risperidone as augmentation treatment for major depressive disorder.Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure.Effect of influenza vaccination on international normalized ratio during chronic warfarin therapy.Tamsulosin for voiding dysfunction in women.Clomiphene for the treatment of male infertility.Description of a medical writing rotation for a postgraduate pharmacy residency program.Use of erythropoiesis-stimulating agents in the treatment of anemia in patients with systolic heart failure.The emerging role of tacrolimus in myasthenia gravis.Outcomes of Pharmacy-Led Hepatitis C Direct-Acting Antiviral Utilization Management at a Veterans Affairs Medical Center.Pregabalin for the Treatment of Restless Legs Syndrome.Economic Outcomes Associated with a Pharmacist-Adjudicated Formulary Consult Service in a Veterans Affairs Medical Center.Memantine for the Treatment of Phantom Limb Pain: A Systematic Review.Characterizing the Severe Reactions of Parenteral Vitamin K1.Desensitization to protein kinase inhibitors: A systematic review.Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.Predictors of glycaemic control among HIV-positive veterans with diabetes.Methods to Promote Preceptor Scholarship through Resident CollaborationGalantamine-associated nightmares and anxiety.Assessment of Postgraduate Year 2 Pharmacy Residency Programs Within the Veterans Affairs Healthcare System.Evaluation of pharmacy services in emergency departments of Veterans Affairs Medical Centers.Impact of phosphodiesterase type 5 inhibitor treatment on the rates of sexually transmitted diseases in a Veterans Affairs Medical Center patient population.Medication adherence in combat veterans with traumatic brain injury.Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis.A protocol to evaluate the efficacy, perceptions, and cost of a cholesterol packaging approach to improve medication adherence.Aripiprazole for Post-traumatic Stress Disorder: A Systematic Review.Inhaler misuse in an older adult population.Combination of inhaled corticosteroid and bronchodilator-induced delirium in an elderly patient with lung disease.The Role of Xanthine Oxidase Inhibitors in Patients with History of Stroke: A Systematic Review.Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome: A Systematic Review.Application of the Layered Learning Practice Model in an Academic Medical Center.Economic outcomes associated with an investigational drug service within a Veterans Affairs health care systemEfficacy and safety of levetiracetam for migraine prophylaxis: A systematic reviewThe role of mirtazapine in patients with fibromyalgia: a systematic reviewTreatment of Demodex-associated inflammatory skin conditions: A systematic reviewThe Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic ReviewTreatment of Helicobacter pylori with nitazoxanide-containing regimens: a systematic reviewAssessing the Economic Value of Pharmacy Resident Participation in an Investigational Drug Service
P50
Q26777082-5C2EB9D3-1338-4A14-96A7-EA76A072814AQ35902065-FC7EE09A-3493-4AE4-A78A-00ACFE1BA3A6Q36883020-22A43BF6-F379-471E-86C3-5DB0C5542F53Q37824372-C757F57D-E4EA-4227-92D5-53D26370AF15Q37960885-81637829-5AB6-4F78-BD40-115028065BD0Q37997104-5E46C00E-E0B7-4A82-96CC-44B48DFA4FF4Q38043968-F69D6A34-C60D-445E-952D-46B17734BCE7Q38064301-C145497D-06A2-4FE0-B1CB-A0A825A45656Q38174567-6D5D2EDE-ECF9-4966-ABF8-D365FF598513Q38226494-08B5E41C-B996-4160-9FFE-D1C5A8658C9EQ38448460-C1E71D57-D554-4B9E-B965-C93568C2BC87Q38754184-AF64CB6C-5587-4DE7-B6F1-9FBDCB7C4FFDQ38811585-AE30DB66-3886-4592-8A21-C340E3A14E6EQ38825981-DEAEA687-8883-4D72-8D22-E64AD716E59CQ38998699-83210069-E75B-4059-B585-C78ED8604DC3Q39182338-484FB8FA-0198-4750-96C4-CE9D912FE34EQ39408626-E11D57F9-D9D6-4351-87F1-E177D7EFC3A4Q39438473-CA3E4581-E0F6-41EC-B4F0-3D52C879C4A7Q42218775-18B25C27-9FBE-44DB-A0E6-696B49A3CA8EQ42852598-E834D14F-B76D-4415-A996-6405FB58E46AQ44971966-BD06742E-713C-4F32-AD3B-BEF4880AC155Q45327730-BA2CBFF3-CB16-4781-8E67-705C250888CAQ45328013-7DDB4764-A25D-4D30-B5CD-38C736F4C689Q45329251-D2D806F4-5A7D-4A17-A6A8-318CEB7497D6Q45330804-49DD0CC2-EFC2-4794-9BB1-403DDF645A21Q46073594-8287E89B-5874-4CAA-BA0B-34DCD4210805Q46494749-868BC80D-5B52-4FC7-B00B-A537EAD78534Q47670517-2BD13A16-CD7B-4253-BF8A-0865C42FBC7CQ47675360-036D6054-ECD6-4007-9EFF-515D6F36195DQ48417998-E99026E0-F898-4CD1-BE29-7C57038FED4BQ49967623-D6E81032-1345-4238-ADBE-336A432DD4FBQ50057540-4E7FA86A-942F-42FA-B6CA-071DEDB014C1Q50437714-A99926CA-DADC-4C47-8825-E4F8EB83A078Q64069424-3B2F3119-92B5-4D84-BD88-3A404A6931C3Q88748798-319F531C-C492-4E3C-B628-507C1AB8FBE4Q88961720-9AC89970-03A5-4AF5-A4D5-B8F399652CABQ90474935-C9021127-7142-4BE4-8DED-69D550900143Q90489934-B9FB3F32-BEF5-4AB1-A85B-FC4873B33DC1Q92403637-F91E5D13-9F05-4A20-8C49-536EAA435CE4Q92975535-FA4F1781-5D0F-4CCB-AA03-62E80CA9C572
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jamie N Brown
@nl
Jamie N Brown
@sl
Jamie N. Brown
@en
Jamie N. Brown
@es
type
label
Jamie N Brown
@nl
Jamie N Brown
@sl
Jamie N. Brown
@en
Jamie N. Brown
@es
prefLabel
Jamie N Brown
@nl
Jamie N Brown
@sl
Jamie N. Brown
@en
Jamie N. Brown
@es
P1153
P106
P1153
56699069300
57191852541
7409453019
P21
P31
P496
0000-0002-6839-5948